Hengrui Medicine gets NMPA nod for HRS-2129 chronic pain trials

Jiangsu Hengrui Medicine Co., Ltd. announced that its subsidiaries, Shandong Shengdi Pharmaceutical Co., Ltd. and Shanghai Hengrui Medicine Co., Ltd., have obtained approval from the National Medical Products Administration (NMPA) for clinical trials of HRS-2129 tablets. The approval covers indications for adult diabetic peripheral neuropathic pain and adult osteoarthritis pain, with trials expected to begin soon.

HRS-2129 is designed to treat acute and chronic pain, and currently, no drugs with the same target mechanism are approved for market in China. The cumulative research and development investment for the HRS-2129 project stands at approximately 112,400,000 yuan.

The company highlighted that drug development, from clinical trial approval to market launch, is a lengthy and complex process with inherent uncertainties. Investors are advised to exercise caution due to the potential risks in drug research and development and subsequent market entry.